Medi-Tate Ltd.
7
0
0
3
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 100/100
42.9%
3 terminated/withdrawn out of 7 trials
50.0%
-36.5% vs industry average
0%
0 trials in Phase 3/4
33%
1 of 3 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (7)
Study to Assess the Efficacy of the iTind in Subjects With Symptomatic BPH
Role: lead
Study to Assess the Efficacy of Medi-Tate iTind Device
Role: lead
Pivotal Study to Assess the Safety and Effectiveness of the iTind Device
Role: lead
A Prospective Study to Observe the Mechanism of Action of the MediTate iTind in Subjects With Symptomatic BPH With MRI
Role: lead
A Multi-center, International Prospective Follow up Study
Role: lead
Study to Assess the Efficacy, Safety and Tolerability of (iTind)
Role: lead
Assessing Safety & Efficacy of MediTate Temporary Implant in Subjects With Benign Prostate Hyperplasia
Role: lead
All 7 trials loaded